SCHEMBL24814401

SCHEMBL24814401

O=C(CS(=O)(=O)c1nccs1)N1Cc2ccc([N+](=O)[O-])cc2C1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DPP7 Q9UHL4 1/20 0.43
▸ NAMPT P43490 1/20 0.39
▸ LMNA P02545 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ CPT2 P23786 1/20 0.36
▸ CPT1A P50416 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ AKR1C3 P42330 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ TAS1R3 Q7RTX0 1/20 0.35
▸ TAS1R1 Q7RTX1 1/20 0.35
▸ TAS1R2 Q8TE23 1/20 0.35
▸ MMP8 P22894 5/20 0.34
▸ MMP3 P08254 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29987551 0.84 MAOB (0.39) NAMPTLMNASMN1; SMN2
SCHEMBL24817127 0.83 MAOB (0.40) NAMPTLMNAKMT2AMEN1CPT2
SCHEMBL24817122 0.83 NAMPT (0.44) DPP7NAMPT
SCHEMBL24815669 0.82 SMN1; SMN2 (0.42) NAMPTLMNAKDM4ENPC1SMN1; SMN2
SCHEMBL29986905 0.82 SMN1; SMN2 (0.42) NAMPTLMNAKDM4ENPC1SMN1; SMN2
SCHEMBL24814391 0.81 RYR2 (0.43) NAMPTLMNAMAPTSMN1; SMN2
SCHEMBL24814740 0.80 NLRP3 (0.35) NAMPTNPC1SMN1; SMN2
SCHEMBL24815670 0.80 NLRP3 (0.35) LMNAKMT2AMEN1NPC1MAPT
SCHEMBL24815798 0.78 NAMPT (0.42) NAMPTKMT2ANPC1SMN1; SMN2
SCHEMBL29987611 0.78 NAMPT (0.42) NAMPTKMT2ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827629-B2 CDGSH iron sulfur domain 2 activators and use thereof NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2023-11-28 — — US disclosed
US-11827629-B2 CDGSH iron sulfur domain 2 activators and use thereof NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2023-11-28 — — US disclosed
US-20220411418-A1 CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2022-12-29 — — US disclosed
WO-2022251343-A2 CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2022-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411418-A1 CDGSH IRON SULFUR DOMAIN 2 ACTIVATORS AND USE THEREOF CISD2, CISD1, FECH DPP7 4414/4885NAMPT 2850/4885LMNA 4440/4885
US-11827629-B2 CDGSH iron sulfur domain 2 activators and use thereof CISD2, CISD1, FECH DPP7 4414/4885NAMPT 2850/4885LMNA 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback